Maggie Wong, a partner in Goodwin’s Technology Companies & Life Sciences Group, focuses her practice primarily on the life sciences sector. Ms. Wong’s representation of start-up and later-stage companies and their investors spans the entire corporate life-cycle, including pre-incorporation planning, general corporate representation and counseling, venture capital financings, public offerings, SEC compliance, and mergers and acquisitions. She also has substantial experience advising on technology transfer, licensing, partnering, distribution and other commercial agreements.

She is a member of the Associate Training Committee for Goodwin’s Technology Companies & Life Sciences Group and a member of the firm's Impact and Responsible Investing Practice and Associate Adviser Network.

Experience

ERFAHRUNG

工作经历

Ms. Wong often serves as outside general counsel to life sciences companies as they develop, in-license and acquire intellectual property and other assets, raise capital to fund their operations and seek to partner their technology or engage in exit transactions. She has represented biotechnology, medical device, diagnostics and specialty pharmaceutical companies and their investors on a range of corporate and transactional matters.

Representative Matters

REFERENZMANDATE

代表事项

Private Company Financing Transactions
  • aTyr Pharma, Inc. in its $76 million Series E Preferred Stock financing
  • Cleave Biosciences, Inc. in its $54 million Series A Preferred Stock financing and $37 million Series B Preferred Stock financing
  • Delinia, Inc. in its $35 million Series A Preferred Stock financing
  • Global Blood Therapeutics, Inc. in its $40.7 million Series A Preferred Stock financing and $48 million Series B Preferred Stock financing
  • MyoKardia, Inc. in its $46 million Series B Preferred Stock financing
  • Spinifex Pharmaceuticals, Inc. in its $45 million Series C Preferred Stock financing
  • Baird Venture Partners in multiple portfolio investments, including Zurex Pharma Inc. and Insightra Medical Inc.
Public Company Financing Transactions
  • Global Blood Therapeutics in its $120 million initial public offering and subsequent $120 million and $125 million follow-on public offerings
  • MyoKardia in its $54 million initial public offering and $65 million follow-on offering
  • aTyr Pharma, Inc. in its $75 million initial public offering
  • Fate Therapeutics, Inc. in its initial public offering, subsequent follow-on public offering and private placement transactions
  • Underwriters in the initial public offering and a subsequent follow-on offering of Regulus Therapeutics Inc.
  • Underwriters in the initial public offering of Conatus Pharmaceuticals Inc.
M&A and Other Strategic Transactions
  • Delinia, Inc. in its sale to Celgene Corporation for $300 million upfront and $475 million in milestone payments
  • F-star Alpha Ltd in its exclusive option agreement with Bristol-Myers Squibb for aggregate consideration of up to $475 million
  • Spinifex Pharmaceuticals in its $200 million upfront sale to Novartis International AG plus undisclosed clinical development and regulatory milestones
  • Artisan Pharma, Inc. in its sale to Asahi Kasei Pharma Corp. for an undisclosed amount
  • Assembly Pharmaceuticals, Inc. in its merger with Ventrus Biosciences, Inc. to become Assembly Biosciences, Inc. (NASDAQ: ASMB)
  • Gallus Biopharmaceuticals, LLC in its acquisition from Centocor Biologics, a subsidiary of Johnson & Johnson, of an FDA-approved, commercially certified biologics manufacturing facility and its entry into an agreement for the commercial manufacture of Remicade and Stelara
  • Alere Inc. in its acquisition from ACON Laboratories, Inc. of ACON’s worldwide lateral flow immunoassay diagnostics business
  • A major buyer of pharmaceutical royalties in the acquisition of a royalty interest from a private university for over $90 million
Professional Activities

Ms. Wong is a member of the American Bar Association and the San Francisco Bar Association.

Professional Experience

Prior to joining Goodwin, Ms. Wong was an associate in the corporate practice group at Heller Ehrman LLP, where she focused her practice on the representation of emerging companies. Before that, she was an associate in the business law department at Cooley LLP. During law school, Ms. Wong was a summer intern in the Office of the General Counsel of the U.S. Securities and Exchange Commission in Washington, D.C.

Recognition

Ms. Wong has been recognized by The Legal 500 U.S. and LMG Life Sciences for her corporate and transactional work in the life science industry. While attending law school, Ms. Wong was a Senior Articles Editor for the Asian Law Journal.

In The News

MELDUNGEN

在新闻中

Credentials

WERDEGANG

专业资格

Education

J.D., 2002
University of California, Berkeley School of Law

(Order of the Coif)

B.A., 1999
Yale University

(cum laude)

Admissions

Bar

California
Get In Touch
KONTAKT
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
搜寻其他律师